Navigation Links
Scientists identify microRNA as possible cause of chemotherapy resistance
Date:3/10/2010

DEAD SEA, Jordan Scientists may have uncovered a mechanism for resistance to paclitaxel in ovarian cancer, microRNA-31, suggesting a possible therapeutic target for overcoming chemotherapy resistance.

Mohamed K. Hassan, Ph.D., a postdoctoral fellow at Hokkaido University in Japan, completed the research as a collaborative study with his colleagues when he was a professional assistant in South Valley University in Egypt. Results of this study were presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.

"MicroRNAs do not code protein, but they regulate other proteins' expression," said Hassan. "So identifying any microRNA as responsible for chemoresistance is, in fact, introducing a real reason for the mechanism."

Ovarian cancer is typically responsive to chemotherapy with paclitaxel, but sometimes cancer cell lines become resistant, which renders chemotherapy useless. Hassan's research team analyzed a set of microRNAs and identified microRNA-31 as being responsible for this chemoresistance. MicroRNA-31 regulates the protein IFITM-1.

"We need to further verify this observation in clinical ovarian cancer samples and find a way to inhibit this target protein to improve the effect of paclitaxel and prevent the risk of recurrence," he said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Dr. David Knepp, a leading ... with Doctors on Liens to bring his ... rare for personal injury victims to have access to ... a lien basis. However, San Diego Chiropractic Group ... chiropractors, M.D., pain management physician, massage, and acupuncture to ...
(Date:3/2/2015)... GBCHealth, a prominent business coalition ... activities and investments in global health issues, today ... members to serve on the organization’s Board of ... Strategist and Co-founder of Partners In Health, and ... Abbasi, General Manager of Global Health and Medical ...
(Date:3/2/2015)... 2015 “ Wants and Needs ” ... AppWatch, which features the latest and coolest mobile applications ... a mobile technology expert and host of NewsWatch, conducted ... app helps people evaluate priorities. , Whether a person ... and Needs app. The app allows people to enter ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... offering gum reshaping procedures. Gum reshaping can involve one or ... or to regenerate lost gum tissue for a more even ... dark gum line treatment that can permanently lighten ... his total smile approach, which involves a personalized treatment plan ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
Breaking Medicine News(10 mins):Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2
... Mayo Clinic researchers determined Math Learning Disorder (LD) is common ... to have Math LD than girls. The research also indicates ... a reading LD, a substantial percentage of children have Math ... through age 19 ranges from 6% to as high as ...
... or Lose it' starts three-year lifestyle campaign to fight osteoporosis ... fractures, a new report explains. , ,'One of the ... exercise,' noted Professor Helmut Minne, IOF Board member and author ... build and maintain strong bones, prevent falls and fractures and ...
... a collaborative work Scientists now been able to map the ... change the face of future medicine. ,The study called ... to chart genetic differences between 269 individuals that originate from ... East and Western Europe. The study involved more than ...
... Mayo Clinic researchers determined Math Learning Disorder (LD) is common ... to have Math LD than girls.//he research also indicates that ... reading LD, a substantial percentage of children have Math LD ... age 19 ranges from 6% to as high as 14%, ...
... Despite the initial efficacy of these therapies against ... Bortezomib (Velcade, formerly PS-341, Millennium, USA) is a ... // multicatalytic cellular enzyme whose activity entails ... pathway. , ,Currently, bortezomib, alone or in ...
... that Bulgaria is to ban the imports of live birds, ... countries reported suspected bird flu outbreaks. The first case of ... Balikesir province near the Aegean Sea in Western Turkey. Following ... are being slaughtered in order to prevent the spread of ...
Cached Medicine News:Health News:Math Learning Disorder Higher In Boys 2Health News:Want Strong Bones: Exercise And Eat Right! 2Health News:Math Learning Disorder Higher in Boys 2Health News:Bortezomib for salvage therapy against progressive myeloma 2
(Date:3/2/2015)... 2, 2015  BC Technical, the nation,s leading ... Eclipse Systems, a Nuclear Imaging service company providing ... of their ongoing vision to provide the best, ... BC Technical continues to expand their reach and ... add valuable resources and knowledge in addition to ...
(Date:3/2/2015)... 2, 2015  DURECT Corporation (Nasdaq: ... and the successful completion of a Phase 1 ... DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical ... metabolic diseases such as nonalcoholic fatty liver disease ... organ injuries such as acute kidney injury (AKI).  ...
(Date:3/2/2015)... GERMANTOWN, Md., March 2, 2015  Intrexon Corporation ... synthetic biology, today announced its fourth quarter and ... Business Highlights and Recent Developments: , Acquired ... a new frontier in cellular therapeutics and other ... molecular engineering of food-grade microbes ( Lactococcus lactis ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
... 2011 Havel,s market leading EchoStim® Echogenic Insulated ... to perform Peripheral Nerve Blocks (PNBs) using nerve ...  The new improved needle has more, brighter, easier ... giving even inexperienced practitioners the benefits of using ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
Antigenic Free Protein S, ELISA Method...
... Clotting Assay for ... the Functional Protein S ... of Factor Va Inhibition ... Human Plasma, free of ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: